Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/183116
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaris, Ata-
dc.contributor.authorLuca, Gianaroli-
dc.contributor.authorKersti, Lundin-
dc.contributor.authorSaria, Mcheik-
dc.contributor.authorEdgar, Mocanu-
dc.contributor.authorRautakallio-Hokkanen, Satu-
dc.contributor.authorTapanainen, Juha S.-
dc.contributor.authorVermeulen, Nathalie-
dc.contributor.authorVeiga, Anna-
dc.date.accessioned2022-02-11T16:35:28Z-
dc.date.available2022-02-11T16:35:28Z-
dc.date.issued2021-
dc.identifier.citationAta, B., Gianaroli, L., Lundin, K., Mcheik, S., Mocanu, E., Rautakallio-Hokkanen, S., ... & Veiga, A. (2021). Outcomes of SARS-CoV-2 infected pregnancies after medically assisted reproduction. Human Reproduction, 36(11), 2883-2890.ca
dc.identifier.issn1460-2350-
dc.identifier.urihttp://hdl.handle.net/2445/183116-
dc.description.abstractThe role of certain viruses in the etiology of some tumors is today indisputable, but there is a lack, however, of an overview of the relationship between viruses and cancer with a multidisciplinary approach. For this reason, the Health Sciences Foundation has convened a group of professionals from different areas of knowledge to discuss the relationship between viruses and cancer, and the present document is the result of these deliberations. Although viruses cause only 10-15% of cancers, advances in oncology research are largely due to the work done during the last century on tumor viruses. The clearest cancer-inducing viruses are: HPV, HBV, HCV, EBV and, depending on the geographical area, HHV-8, HTLV-1 and HIV. HPVs, for example, are considered to be the causative agents of cervical carcinomas and, more recently, of a proportion of other cancers. Among the Herpes viruses, the association with the development of neoplasms is well established for EBV and HHV-8. Viruses can also be therapeutic agents in certain neoplasms and, thus, some oncolytic viruses with selective tropism for tumor cells have been approved for clinical use in humans. It is estimated that the prophylaxis or treatment of viral infections could prevent at least 1.5 million cancer deaths per year.ca
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoengca
dc.publisherOxford Academic Pressca
dc.relation.isformatofReproducció del document publicat a: https;//doi.org/10.1093/humrep/deab218-
dc.relation.ispartofHuman reproduction, 2021, vol 36, num 11, p. 2883-2890-
dc.relation.urihttps;//doi.org/10.1093/humrep/deab218-
dc.rightscc by-nc (c) Baris, Ata et al, 2021-
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationCOVID-19-
dc.subject.classificationReproducció assistida-
dc.subject.otherCOVID-19-
dc.subject.otherReproductive technology-
dc.titleOutcomes of SARS-CoV-2 infected pregnancies after medically assisted reproductionca
dc.typeinfo:eu-repo/semantics/articleca
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca
dc.identifier.pmid34515777-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
deab218.pdf313.46 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons